Tizanidine Indications
Tizanidine is FDA-approved for the management of spasticity, specifically as a short-acting agent reserved for daily activities and times when relief of spasticity is most important 1.
Primary FDA-Approved Indication
Tizanidine is indicated for spasticity management in conditions including 1, 2, 3:
- Multiple sclerosis (MS) - chronic stroke patients specifically benefit with improvement in spasticity and pain without loss of motor strength
- Spinal cord injury
- Acquired brain injury (including stroke)
The drug should be used when spasticity results in 2:
- Pain
- Poor skin hygiene
- Decreased function
Mechanism and Classification
Tizanidine is an α2-adrenergic receptor agonist and centrally acting spasmolytic agent 4. It is a clonidine derivative but has fewer cardiovascular effects on heart rate and blood pressure compared to clonidine 4.
Off-Label Uses Supported by Evidence
While not FDA-approved, tizanidine shows efficacy in 5, 6:
Pain Syndromes
- Muscle relaxation for acute low back pain (efficacious in 8 trials) 7
- Myofascial pain - particularly chronic neck and lower back pain with myofascial component 6
- Trigeminal neuralgia 6
- Neuropathic pain 8
Perioperative Applications
Mounting evidence supports perioperative benefits including 4:
- Improved postoperative pain control
- Decreased midazolam dose requirements
- Reduced opioid consumption
- Hemodynamic stability
Gastroprotection
Tizanidine enhances analgesic and anti-inflammatory effects of NSAIDs while providing gastroprotection, improving gastrointestinal tolerability 9, 8.
Dosing Considerations
Standard dosing: Start with 2 mg orally at night; if tolerated, increase by 2-4 mg daily up to 8 mg every 8 hours 5.
The drug has a short duration of action with significant interpatient variability, requiring individualized titration 1, 3.
Critical Safety Considerations
Absolute Contraindications
- Concomitant use with CYP1A2 inhibitors (ciprofloxacin, fluvoxamine) - contraindicated due to significantly reduced clearance 4
- Concomitant methadone use - increased risk of prolonged QTc 5
Use with Extreme Caution
- Hepatic or renal dysfunction (creatinine clearance <25 mL/min requires 50% dose reduction) 1, 5
- Elderly patients - significant sedative and hypotensive effects 4
- Women taking oral contraceptives - 50% reduction in clearance requires dose adjustment 4, 1
- Alcohol use - additive CNS depression and 20% increase in AUC with 15% increase in Cmax 1, 10
Withdrawal Risk
Never discontinue abruptly - risk of rebound tachycardia, hypertension, and hypertonia requires slow tapering if used long-term 4. This is particularly critical in patients on high doses for extended periods.
Advantages Over Other Muscle Relaxants
Tizanidine is not on the 2023 American Geriatrics Society Beers Criteria for potentially inappropriate medications in older adults, unlike most other skeletal muscle relaxants 8. It demonstrates:
- Lower incidence of adverse events compared to baclofen (injury, delirium, falls, opioid overdose)
- No association with Alzheimer's disease risk (unlike orphenadrine)
- No serotonin syndrome risk (unlike metaxalone with serotonergic drugs)
- No physically addictive or abuse properties (unlike carisoprodol and diazepam)
- No significant pharmacokinetic changes in CYP2C19 poor metabolizers (unlike diazepam and carisoprodol) 8